MedTrace Logo

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914

NCT01929629 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-04-15

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of orally administered AZD0914 in healthy adult subjects.

Conditions

  • Gonococcal (GC) Infection

Interventions

DRUG

Part A

Single ascending doses

DRUG

Part B

Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.

Sponsors & Collaborators

Principal Investigators

  • David Mathews, MD · Quintiles Phase I unit, Kansas

  • Humphrey Gardener, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01929629 on ClinicalTrials.gov